Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact










Isin US1510201049
Ticker CELG
Company CELGENE
Currency $
Price
Aware Investor Index (AII) 0.5678
Recommendation BUY
P/E 55.04
ROE 18.62 %
Capitalization 70,939,164,000 $
Dividend Yield 0.00 %
P/S 5.46
AII Position 282
P/E Position 601
ROE Position 171
Capitalization Position 125
Dividend Yield Position 598
Sales 13,003,000,000 $
10-Year Average Earnings 1,288,873,600 $
Shares Outstanding 808,700,000
Equity 6,921,000,000 $
Dividend per Share 0 $
Industry Biotechnology
Country United States
CELGENE Investor Relations Web Site http://ir.celgene.com







Sales:

YEAR MONTH AMOUNT
2017 12 13,003,000,000.00 $
2016 12 11,229,000,000.00 $
2015 12 9,256,000,000.00 $
2014 12 7,670,400,000.00 $
2013 12 6,493,900,000.00 $

Earnings:

YEAR MONTH AMOUNT
2017 12 2,940,000,000.00 $
2016 12 1,999,000,000.00 $
2015 12 1,602,000,000.00 $
2014 12 1,999,900,000.00 $
2013 12 1,449,900,000.00 $
2012 12 1,456,180,000.00 $
2011 12 1,318,150,000.00 $
2010 12 880,512,000.00 $
2009 12 776,747,000.00 $
2008 12 -1,533,653,000.00 $

Equity:

YEAR MONTH AMOUNT
2017 12 6,921,000,000.00 $
2016 12 6,600,000,000.00 $
2015 12 5,919,000,000.00 $
2014 12 6,524,800,000.00 $
2013 12 5,589,900,000.00 $
2012 12 5,694,467,000.00 $
2011 12 5,512,727,000.00 $

Shares Outstanding:

YEAR MONTH AMOUNT
2017 12 808,700,000
2016 12 803,300,000
2015 12 824,900,000
2014 12 836,000,000
2013 12 430,300,000
2012 12 440,796,000
2011 12 422,987,284

 












Bloomberg News for CELGENE:



Google News for CELGENE:

Seeking Alpha - 3 days ago
Celgene Yields The Most
Such is the case with Celgene (CELG) now trading not far off multi-year lows despite the reality that a key drug in Revlimid actually has years ...
Investopedia
Celgene (CELG) Outpaces Stock Market Gains: What You Should ...
Investors will be hoping for strength from CELG as it approaches its next earnings release, which is expected to be October 25, 2018.
Top Stocks News (press release)
Celgene backs away from OncoMed's navicixizumab
OncoMed Pharmaceuticals (NASDAQ:OMED) announces that Celgene (NASDAQ:CELG) has decided not to exercise its option to license ...
NMSU Nеws
Celgene (CELG) Shares Cross Below 200 DMA
In trading on Tuesday, shares of Celgene Corp (Symbol: CELG) crossed below their 200 day moving average of $91.55, changing hands as ...
Zacks.com - 1 day ago
Celgene (CELG) Downgraded by BidaskClub
BidaskClub downgraded shares of Celgene (NASDAQ:CELG) from a buy rating to a hold rating in a research report released on Thursday, ...
Seeking Alpha - 1 day ago
Celgene (CELG) Stock Sinks As Market Gains: What You Should ...
CELG will be looking to display strength as it nears its next earnings release, which is expected to be October 25, 2018. In that report, analysts ...
Nasdaq - 4 Sep 2018
Will Revlimid's Patent Protection Hold Up For Celgene?
Celgene trades at a discount because its key drug, Revlimid, faces potential generic competition prior to the expiration of its patents in 2023.
GV Times
Celgene Corp. (CELG) Presents at Morgan Stanley Global ...
Celgene Corp. (NASDAQ:CELG) Morgan Stanley Global Healthcare Conference Call September 14, 2018 11:40 AM ET. Executives.
Fairfield Current
Celgene Corporation (CELG) CEO Mark Alles on Citi's 13th Annual ...
Celgene Corporation (NASDAQ:CELG) Citi's 13th Annual Biotech Conference Call September 6, 2018 12:00 PM ET. Executives. Mark Alles ...
Baseball Daily Digest
Did An Insider Sell Their Shares In Celgene Corporation (NASDAQ ...
Did An Insider Sell Their Shares In Celgene Corporation (NASDAQ:CELG)? ... Celgene Corporation, a biopharmaceutical company, engages in ...


Back